Přístupnostní navigace
E-přihláška
Vyhledávání Vyhledat Zavřít
Detail publikace
HRABĚTA, J. STIBOROVÁ, M. ADAM, V. KIZEK, R. ECKSCHLAGER, T.
Originální název
Histone deacetylase inhibitors in cancer therapy. A review
Typ
článek v časopise ve Web of Science, Jimp
Jazyk
angličtina
Originální abstrakt
Different HDAC inhibitors induce cancer cell death by different mechanisms that include changes in gene expression and alteration of both histone and non-histone proteins. Enhanced histone acetylation in tumors results in modification of expression of genes involved in cell signaling. Inhibition of HDACs causes changed expression in 2-10 % of genes involved in important biological processes. The results of experiments and clinical studies demonstrate that combination of HDAC inhibitors with some anticancer drugs have synergistic or additive effects.
Klíčová slova
chromatin remodeling, histone acetylation, histone deacetylases, histone deacetylase inhibitors, combined treatment modalities, mechanisms of combined treatment
Autoři
HRABĚTA, J.; STIBOROVÁ, M.; ADAM, V.; KIZEK, R.; ECKSCHLAGER, T.
Rok RIV
2014
Vydáno
1. 6. 2014
ISSN
1213-8118
Periodikum
Biomedical Papers
Ročník
158
Číslo
2
Stát
Česká republika
Strany od
161
Strany do
169
Strany počet
9
BibTex
@article{BUT112436, author="Jan {Hraběta} and Marie {Stiborová} and Vojtěch {Adam} and René {Kizek} and Tomáš {Eckschlager}", title="Histone deacetylase inhibitors in cancer therapy. A review", journal="Biomedical Papers", year="2014", volume="158", number="2", pages="161--169", doi="10.5507/bp.2013.085", issn="1213-8118" }